Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
UNITED STATES OF AMERICA EX REL. DONALD R. GALMINES v. NOVARTIS PHARMACEUTICALS CORPORATION
Case Number:
2:06-cv-03213
Court:
Nature of Suit:
Other Statutes: Other Statutory Actions
Judge:
Firms
-
October 05, 2016
Novartis Pays $35M To End Elidel Off-Label Marketing Suit
Novartis AG will pay more than $35 million to end a suit in Pennsylvania federal court accusing it of violating federal and state false claims acts by marketing the eczema cream Elidel for use on infants, even though it was only approved for older patients, the whistleblower said Wednesday.
-
August 20, 2015
Whistleblower Can't Depose Novartis Ex-CEO In FCA Suit
The U.S. won't be able to depose the former CEO of Novartis Pharmaceuticals Corp. because the government and its whistleblower in the False Claims Act suit haven't proven that the information can't be acquired elsewhere in a less-burdensome fashion, a Pennsylvania federal judge said Wednesday.
-
March 19, 2015
FCA Whistleblowers Poised To Target Post-Employment Fraud
A new False Claims Act ruling against Novartis Pharmaceuticals Corp. in Pennsylvania federal court shows that whistleblowers will increasingly be able to target fraud that took place years after they left their jobs, attorneys say.
-
November 05, 2013
State Claims Reinstated In Novartis Elidel FCA Suit
The federal judge overseeing a former Novartis Pharmaceuticals Corp. employee's whistleblower lawsuit accusing the drugmaker of ripping off Medicaid by promoting off-label uses of eczema treatment Elidel on Tuesday reinstated some claims she had previously dismissed.
-
August 27, 2013
Novartis Can't Rush Appeal In Elidel FCA Suit, Judge Says
A Pennsylvania federal judge on Friday denied Novartis Pharmaceuticals Corp.'s request to file an interlocutory appeal on part of her decision trimming down a whistleblower suit alleging the drugmaker defrauded government health care programs by promoting off-label uses of eczema treatment Elidel.
-
July 08, 2013
Novartis Whistleblower Wants State FCA Claims Revived
A former Novartis Pharmaceuticals Corp. employee on Wednesday challenged a Pennsylvania federal judge's decision to ax certain state False Claims Act claims from his whistleblower suit accusing the pharmaceutical giant of ripping off Medicaid by promoting off-label uses of eczema treatment Elidel.
-
June 14, 2013
Novartis Can't Duck Elidel FCA Suit, But Kickback Claims Cut
A Pennsylvania federal judge on Thursday refused to dismiss a former Novartis Pharmaceuticals Corp. employee's whistleblower lawsuit, which accuses the drugmaker of ripping off Medicaid by promoting off-label uses of eczema treatment Elidel, but stripped anti-kickback claims from the suit.
-
October 26, 2012
Novartis Given Reprieve In Elidel FCA Suit
A Pennsylvania federal judge on Friday dismissed a former Novartis Pharmaceuticals Corp. employee's False Claims Act suit accusing the company of off-label marketing and kickbacks related to eczema treatment Elidel, but gave the former employee leave to amend his complaint.